Abstract 1218
Background
Taxanes (TAX) are the current first-line treatment for advanced cutaneous angiosarcoma (CAS). On the other hand, eribulin (ERB) is a nontaxane microtubule inhibitor approved for treatment of advanced sarcoma in Japan. However, no study has evaluated ERB in CAS patients. We hypothesized that ERB would be well tolerated and active in patients with TAX-resistant CAS because TAX and ERB have different mechanisms of action to inhibit microtubule formation.
Methods
We designed a single-arm, prospective observational study of ERB administered at dose of 1.4 mg/m2 on days 1 and 8 in every 21 days. TAX-resistant, advanced CAS patients for whom ERB use was planned were enrolled. The primary endpoint is overall survial (OS), and the secondary endpoint, response ratio (RR), progression-free survival (PFS), and toxicity assessment. The estimated median OS in a previous clinical study (ANGIOTAX), in which patients received TAX as the second-line treatment, was 6 months, so we set this number as the threshold and expected a 6-month OS of 70% with ERB treatment. Based on these numbers, the required number of patients to be enrolled was calculated as 31; thus, we set 35 patients as the target number.
Results
At the time of submissiion, 25 CAS patients, median age 74, were enrolled. All had prior TAX exposure. In all but 1 patient the primary tumor was in the head and neck, and 10 patients had a metastatic tumor. The performance status (PS) was generally good: 22 with PS0 or 1. The median follow-up period was 161 (47-464) days. The respective Kaplan-Meier estimates for OS and PFS rates at 6 months were 70% and 31%. The respective median OS and PFS were not-reached and 94 days. The respective RR at weeks 7, 13, and 25 were 24%, 12% and 11%. No death related to treatment was observed. Although 9 patients experienced >grade 3 toxicity (7, neutropenia; 2, anemia; 1, retroperitoneal abscess), they all recovered.
Conclusions
ERB is a well-tolerated regimen with promising activity in TAX-resistant CAS. The common toxicity is neutropenia, which requires growth factor support. This study is underway and enrollment is expected to be completed in 2018. This study may provide a new treatment option for patients with PTX-resistant CAS.
Clinical trial identification
UMIN000023331.
Legal entity responsible for the study
University of Tsukuba.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract